Intravacc has announced that a Phase 1 study of Avacc 10 intranasal vaccine as a booster against SARS-CoV-2 induced a mucosal response in subjects who received the higher of two doses tested, and the vaccine was well tolerated. The company announced in November 2022 that it was initiating the Phase 1 study of Avacc 10.
According to Intravacc, the study enrolled 36 healthy volunteers, aged 18-55, who received intranasal delivery of either a low dose of vaccine, a high dose of vaccine, outer membrane vesicles only, or placebo. All received a second intranasal dose 3 weeks after the first and were followed for 6 months after vaccination.
Intravacc VP of Research & Development Dinja Oosterhoff commented, “The very encouraging immune response results from our Avacc 10 Phase 1 trial clearly demonstrates that we can use an OMV based vaccine to booster the immune response.”
Chairman & CEO Jan Groen said, “This FIH intranasal vaccine study marks a significant milestone for Intravacc’s flagship OMV-based vaccine platform. Now Intravacc is also developing an intranasal vaccine for gonorrhea targeting the FIH in Q4 2025. The company has already licensed other OMV-based vaccines to large pharma companies.”
Read the Intravacc press release.
